Asset Details
Do you wish to reserve the book?
Developing Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Developing Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction
Do you wish to request the book?
Developing Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Developing Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction
2018
Overview
Genomic characterization of cancers has shown that some oncogenic alterations occur at very low frequency and are shared across tumor types. For example,
NTRK
translocations mediate malignant transformation and are observed in less than 1% of cancers and in more than 20 cancer types.
1
The genes
NTRK1
,
NTRK2
, and
NTRK3
encode for the tropomyosin receptor kinase (TRK) proteins TRKA, TRKB, and TRKC, respectively. In this issue of the
Journal
, Drilon et al.
2
report a pooled analysis of three prospective clinical trials testing larotrectinib, a TRK inhibitor, in 55 patients. The overall response rate was 80%, and 71% of the responses . . .
Publisher
Massachusetts Medical Society
Subject
